Sugi Predict

Sugi Predict / Targets / CYP4X1

CYP4X1

Cytochrome P450 4X1 · Q8N118 · CYP4X1 on Sugi Atlas →

565 patent compounds predicted against CYP4X1, 511 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2898679 SCHEMBL2898679 1.00 1/20
SCHEMBL2898801 SCHEMBL2898801 1.00 1/20
SCHEMBL2902603 SCHEMBL2902603 1.00 1/20
SCHEMBL2900857 SCHEMBL2900857 0.91 1/20
SCHEMBL2896472 SCHEMBL2896472 0.88 1/20
SCHEMBL14447488 SCHEMBL14447488 0.88 1/20
SCHEMBL2898585 SCHEMBL2898585 0.87 1/20
SCHEMBL13384055 SCHEMBL13384055 0.87 1/20
SCHEMBL13384138 SCHEMBL13384138 0.87 1/20
SCHEMBL2903365 SCHEMBL2903365 0.86 1/20
SCHEMBL14266901 SCHEMBL14266901 0.86 1/20
SCHEMBL14573956 SCHEMBL14573956 0.86 1/20
SCHEMBL2900814 SCHEMBL2900814 0.85 1/20
SCHEMBL2901461 SCHEMBL2901461 0.85 1/20
SCHEMBL2903849 SCHEMBL2903849 0.85 1/20
SCHEMBL13433927 SCHEMBL13433927 0.85 1/20
SCHEMBL2895313 SCHEMBL2895313 0.84 1/20
SCHEMBL2896195 SCHEMBL2896195 0.84 1/20
SCHEMBL2897932 SCHEMBL2897932 0.84 1/20
SCHEMBL2898972 SCHEMBL2898972 0.84 1/20

Clinical trials — most relevant to CYP4X1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients PHASE3COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis PHASE2RECRUITING
Oral Cannabidiol for Opioid Withdrawal PHASE1/PHASE2COMPLETED
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors PHASE2RECRUITING
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma PHASE1COMPLETED
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors PHASE1UNKNOWN
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 PHASE1COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects PHASE1NOT_YET_RECRUITING
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease PHASE1COMPLETED
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally PHASE1COMPLETED
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors PHASE1COMPLETED
To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants PHASE1COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases PHASE1COMPLETED
Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects PHASE1COMPLETED
Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation PHASE1COMPLETED
4-methylpyrazole and Acetaminophen Metabolism EARLY_PHASE1COMPLETED
CYP3A4 Activity and Mineral Homeostasis EARLY_PHASE1COMPLETED
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 nanCOMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer nanCOMPLETED
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline nanCOMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
Cholesterol Metabolites as Markers for CYP3A Induction nanCOMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients nanCOMPLETED
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease nanCOMPLETED
Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain nanUNKNOWN
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
Spartan FRX Project Reproducibility Study nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP4X1 binder may also engage these)

ProteinNameSimilarity
CYP4Z1 Cytochrome P450 4Z1 0.999 landscape →
Q6A152 — 0.996 Q6A152 →
CYP4F2 Cytochrome P450 4F2 0.996 landscape →
Q64462 — 0.996 Q64462 →
P15129 — 0.995 P15129 →
P51869 — 0.995 P51869 →
Q8K4D6 — 0.994 Q8K4D6 →
P15128 — 0.993 P15128 →
CYP4F3 Cytochrome P450 4F3 0.993 landscape →
P24464 — 0.992 P24464 →
CYP4F11 Cytochrome P450 4F11 0.991 landscape →
Q9EP75 — 0.991 Q9EP75 →
P51871 — 0.991 P51871 →
P20817 — 0.990 P20817 →
P51870 — 0.989 P51870 →
P20816 — 0.989 P20816 →
P33274 — 0.988 P33274 →
CYP4F12 Cytochrome P450 4F12 0.988 landscape →
CYP4B1 Cytochrome P450 4B1 (EC 1.14.14.1) (CYPIVB1) 0.988 landscape →
O88833 — 0.988 O88833 →
Q9VG40 — 0.987 Q9VG40 →
Q9GLL1 — 0.987 Q9GLL1 →
A2A974 — 0.987 A2A974 →
P08516 — 0.986 P08516 →
Q0IIF9 — 0.986 Q0IIF9 →
Q99N16 — 0.986 Q99N16 →
CYP4F8 Cytochrome P450 4F8 0.985 landscape →
Q3MID2 — 0.984 Q3MID2 →
Q64481 — 0.984 Q64481 →
Q91WL5 — 0.984 Q91WL5 →